Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTYT93M)

• DTT Name: MAP kinase p38 (MAPK12) DTT Info
• Gene Name: MAPK12

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SM-101	DMFX9O6	Idiopathic thrombocytopenic purpura	3B64.10	Approved (orphan drug)	[1]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARRY-797	DMJ48AB	Dilated cardiomyopathy	BC43.0	Phase 2	[2]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[3]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KC706	DMBX6C7	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[4]
SB 235699	DMNH8XU	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[5]

14 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[6]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[7]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[8]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[8]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[8]
KT-5720	DM9J50F	Discovery agent	N.A.	Investigative	[8]
ML-3163	DM3S5UC	Discovery agent	N.A.	Investigative	[9]
ML-3375	DMXJY6W	Discovery agent	N.A.	Investigative	[10]
ML-3403	DMTQWI8	Discovery agent	N.A.	Investigative	[10]
Phosphonothreonine	DMTFHPI	Discovery agent	N.A.	Investigative	[11]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[8]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[8]
RWJ-68354	DMNLVRS	Discovery agent	N.A.	Investigative	[12]
STAUROSPORINONE	DMU2H4K	Discovery agent	N.A.	Investigative	[8]

References

• [1] Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
• [2] Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
• [3] P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
• [4] KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
• [5] Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
• [6] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [7] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [8] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [9] From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem. 2002 Jun 20;45(13):2733-40.
• [10] Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
• [11] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [12] Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.